LifeArc portfolio company RQ Bio’s antibody enters clinical trials
LifeArc Ventures’ portfolio company RQ Biotechnology has announced that the first of its discovered monoclonal antibodies to…
LifeArc’s Head of Ventures, Clare Terlouw speaks with @FT Global Pharma Correspondent @hannahkuchler discussing RQ… https://t.co/fqrxEXr3Xf
Evolving our science to solve complex healthcare challenges
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis
Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.
LifeArc announces £10m funding call for new chronic respiratory infection therapies
First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge
£100m programme to transform care for people living with chronic lung conditions
More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic fibrosis.
LifeArc responds to the Government’s renewed pledge to increase R&D funding
LifeArc CEO Dr Melanie Lee welcomes the Government’s restatement of its commitment to increase R&D funding in today’s Autumn statement: “Today the Chancellor made it clear that UK life science is a key driver of growth. “I am delighted that promises to raise the research and development (R&D) budget have been protected. It is the […]
LifeArc funds home monitoring trials for people with chronic respiratory conditions
Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.
LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
Call for Government to place medical research at the heart of economic plans
Ahead of the Autumn Statement, LifeArc and other leading life science organisations have written to the Chancellor…